Plus Therapeutics Inc (PSTV) is now in the Undervalued zone, suggesting that its current forward PS ratio of 12.70 is considered Undervalued compared with the five-year average of -1.24. The fair price of Plus Therapeutics Inc (PSTV) is between 0.32 to 0.48 according to relative valuation method. Compared to the current price of 0.30 USD , Plus Therapeutics Inc By Undervalued By 6.5%.

Relative Value

Fair Zone

0.32-0.48

Current Price：0.30

6.5%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Plus Therapeutics Inc (PSTV) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Plus Therapeutics Inc (PSTV) has a current Price-to-Book (P/B) ratio of 14.45. Compared to its 3-year average P/B ratio of 2.43, the current P/B ratio is approximately 494.90% higher. Relative to its 5-year average P/B ratio of 2.18, the current P/B ratio is about 562.53% higher. Plus Therapeutics Inc (PSTV) has a Forward Free Cash Flow (FCF) yield of approximately -20.68%. Compared to its 3-year average FCF yield of -143.09%, the current FCF yield is approximately -85.54% lower. Relative to its 5-year average FCF yield of -111.40%, the current FCF yield is about -81.43% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PSTV competitors is 50.23, providing a benchmark for relative valuation. Plus Therapeutics Inc Corp (PSTV.O) exhibits a P/S ratio of 12.70, which is -74.72% above the industry average. Given its robust revenue growth of -4.05%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PSTV increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PSTV in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PSTV currently overvalued or undervalued?

What is Plus Therapeutics Inc (PSTV) fair value?

PSTV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Plus Therapeutics Inc (PSTV) is between 0.32 to 0.48 according to relative valuation method.

How does PSTV's valuation metrics compare to the industry average?

The average P/S ratio for PSTV's competitors is 50.23, providing a benchmark for relative valuation. Plus Therapeutics Inc Corp (PSTV) exhibits a P/S ratio of 12.70, which is -74.72% above the industry average. Given its robust revenue growth of -4.05%, this premium appears unsustainable.

What is the current P/B ratio for Plus Therapeutics Inc (PSTV) as of Mar 03 2026?

As of Mar 03 2026, Plus Therapeutics Inc (PSTV) has a P/B ratio of 14.45. This indicates that the market values PSTV at 14.45 times its book value.

What is the current FCF Yield for Plus Therapeutics Inc (PSTV) as of Mar 03 2026?

As of Mar 03 2026, Plus Therapeutics Inc (PSTV) has a FCF Yield of -20.68%. This means that for every dollar of Plus Therapeutics Inc's market capitalization, the company generates -20.68 cents in free cash flow.

What is the current Forward P/E ratio for Plus Therapeutics Inc (PSTV) as of Mar 03 2026?

As of Mar 03 2026, Plus Therapeutics Inc (PSTV) has a Forward P/E ratio of -3.83. This means the market is willing to pay $-3.83 for every dollar of Plus Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Plus Therapeutics Inc (PSTV) as of Mar 03 2026?

As of Mar 03 2026, Plus Therapeutics Inc (PSTV) has a Forward P/S ratio of 12.70. This means the market is valuing PSTV at $12.70 for every dollar of expected revenue over the next 12 months.

PSTV Valuation